About Putative cleavage and polyadenylation specificity factor subunit 4-like protein
Putative cleavage and polyadenylation specificity factor subunit 4-like protein (CPSF4L) is a protein
from Homo sapiens identified by UniProt accession
A6NMK7, 179 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | Putative cleavage and polyadenylation specificity factor subunit 4-like protein |
|---|
| UniProt accession | A6NMK7 |
|---|
| Gene | CPSF4L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 179 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (15)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.08
- reticulocyte count · score 0.07
- isolated asymptomatic elevation of creatine phosphokinase · score 0.07
- mean corpuscular volume · score 0.06
- erythrocyte count · score 0.06
- reticulocyte measurement · score 0.05
- pentosuria · score 0.05
- mean corpuscular hemoglobin · score 0.03
- jaw fracture · score 0.03
- white matter microstructure measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6NMK7-F1 | alphafold | PREDICTED | 84.67 | — |
Amino-acid sequence (179 residues)
MQEVIAGLER FTFAFEKDVE MQKGTGLLPF QGMDKSASAV CNFFTKGLCE KGKLCPFRHD RGEKMVVCKH WLRGLCKKGD HCKFLHQYDL TRMPECYFYS KFGDCSNKEC SFLHVKPAFK SQDCPWYDQG FCKDGPLCKY RHVPRIMCLN YLVGFCPEGP KCQFAQKIRE FKLLPGSKI
Explore Putative cleavage and polyadenylation specificity factor subunit 4-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets